Endocrinology-Hormones

Faznolutamide is an androgen receptor inhibitor that interferes with androgen signaling. This compound exhibits significant antiandrogenic activity, making it a valuable tool for investigating androgen-dependent biological processes. It is used in research focused on prostate cancer and other conditions influenced by androgens.

Bifluranol is an androgen receptor inhibitor that functions by blocking the action of androgens, which are hormones that can promote the growth of certain cancers. This compound exhibits anti-androgenic activity, making it valuable in research addressing hormone-dependent cancers, such as prostate cancer. Bifluranol can be utilized in studies focused on understanding androgen signaling pathways and developing therapeutic strategies targeting androgen-related conditions.

Androgen receptor-IN-5 is a potent inhibitor of the androgen receptor, demonstrating significant anticancer activity. This compound also disrupts the production of pro-inflammatory cytokines, including IL-17A, IL-17F, and IFN-γ, making it a valuable tool for studying androgen receptor signaling and its role in cancer and immune responses. Its multifaceted activity positions Androgen receptor-IN-5 as a promising candidate for research in cancer therapeutics and inflammation modulation.

YXG-158 is an orally active androgen receptor (AR) degrader and CYP17A1 inhibitor. It exhibits AR degradation activity with a DC50 value of 1.28 μM and inhibits CYP17A1 with an IC50 value of 100 nM. This compound is particularly relevant for research applications focused on enzalutamide-resistant prostate cancer, providing a valuable tool for investigating therapeutic strategies in this context.

AR/AR-V7-IN-1 is a potent inhibitor of the androgen receptor (AR) and its splice variant AR-V7, with an IC50 of 172.85 nM. This compound effectively suppresses cell proliferation in LNCaP and 22RV1 cell lines, exhibiting IC50 values of 4.87 μM and 2.07 μM, respectively. Additionally, AR/AR-V7-IN-1 demonstrates significant tumor growth inhibition in 22RV1 xenograft models, making it a valuable tool for prostate cancer research.

VPC13163 is a potent inhibitor of the androgen receptor (AR) BF3 domain, exhibiting an IC50 value of 0.31 µM. This compound demonstrates significant anticancer activity, making it a valuable tool for research in prostate cancer and other androgen-dependent malignancies. Its ability to selectively target the AR BF3 domain allows for the exploration of new therapeutic strategies in androgen receptor-mediated pathways.

AR Antagonist 6 is a diphenyl ether compound that acts as a selective androgen receptor (AR) antagonist, binding to the receptor with an affinity of 120 nM. This compound demonstrates low toxicity and shows promising in vitro activity in the golden Syrian hamster ear model. It serves as a valuable tool for research applications involving the modulation of androgen receptor signaling in various biological contexts.

Androgen receptor-IN-4 is a potent androgen receptor inhibitor that selectively targets the androgen receptor signaling pathway. This compound is particularly valuable for investigating the mechanisms underlying androgen-dependent conditions, including Kennedy's disease. Its application in research can contribute to a better understanding of therapeutic strategies for androgen receptor-related disorders.

AR Antagonist 2 is a potent inhibitor of the androgen receptor (AR), demonstrating an IC50 of 0.95 μM. This compound is crucial for cancer research, particularly in studies exploring androgen-driven pathways and potential therapeutic strategies in hormone-dependent malignancies. Its efficacy makes it a valuable tool for investigating AR-related biological mechanisms.

M17-B15 is an androgen receptor dimerization inhibitor that demonstrates an IC50 of 30 nM. By effectively disrupting androgen receptor self-association, M17-B15 suppresses androgen receptor signaling pathways. This compound exhibits significant anti-prostate cancer efficacy in both in vitro studies and in mouse xenograft tumor models, making it a valuable tool for research in prostate cancer biology.

Androgen receptor-IN-3 is a selective inhibitor of the androgen receptor (AR), effectively reducing AR-driven transcriptional activity in LNCaP prostate cancer cells, with an IC50 of 5.04 μM. This compound is primarily utilized in research applications investigating androgen receptor signaling pathways and their role in prostate cancer progression. Its inhibitory effects on AR activity present a valuable tool for studying potential therapeutic strategies targeting androgen-dependent tumors.

Carbazole derivative 1 is an androgen receptor inhibitor that effectively reduces androgen and estrogen levels in mammals, including humans. This compound demonstrates significant potential in research applications focusing on hormone-related disorders and cancer treatments involving hormonal regulation. Its unique mechanism may provide insights into therapeutic strategies for managing conditions influenced by androgen and estrogen signaling pathways.

Coumestrol is a phytoestrogen that targets the estrogen receptor, functioning as an ERR inhibitor. It demonstrates significant anti-proliferative activity against ES2 cells, with an IC50 value of 50 μM. Coumestrol is of interest in research related to cancer, neurological disorders, and autoimmune diseases due to its potential therapeutic effects.

Licoflavone C is a viral endonuclease inhibitor with broad-spectrum antiviral activity. It exhibits estrogen-like properties and effectively inhibits the replication of various bunyaviruses, including severe fever with thrombocytopenia syndrome virus (SFTSV) and lymphocytic choriomeningitis virus, through a non-substrate competitive mechanism. Licoflavone C demonstrates an IC50 of 35.5 μM against SFTSV CEN, with a Kd of 9.53 μM. Additionally, it exhibits low cytotoxicity and genotoxicity while inducing apoptosis and alleviating chemotherapy-induced chromosomal damage. This compound is valuable for research on viral infections, particularly mechanisms related to severe fever with thrombocytopenia syndrome.

α-Zearalenol is a mycotoxin that acts as an inhibitor of estrogen receptors (ER). As a derivative of zearalenone, it exhibits a high affinity for these receptors, leading to significant xenoestrogenic effects that can result in reproductive disorders in animals. This compound is utilized in research to study the impact of estrogenic exposure and its implications in endocrine disruption and reproductive health.

3-Formylsalicylic acid is a noncompetitive inhibitor of estrone sulfatase, displaying an IC50 value of 0.15 mM and a Ki value of 0.12 mM. This compound demonstrates low acute toxicity, making it a suitable candidate for research applications aimed at studying estrogen metabolism and related pathways in cancer biology. Its inhibitory effects on estrone sulfatase may provide insights into therapeutic strategies for hormone-dependent tumors.

TPBM is a selective estrogen receptor α (ERα) inhibitor with an IC50 value of 9 μM for the 17β-estradiol (E2)-ERα complex. This compound effectively diminishes the recruitment of E2·ERα to endogenous estrogen-responsive genes. Additionally, TPBM demonstrates the capacity to inhibit E2-dependent proliferation of ERα-positive cancer cells, exhibiting an IC50 of 5 μM. Notably, TPBM is non-toxic to normal cells and does not interfere with estrogen-independent cell growth, making it a valuable tool for research in hormone-responsive signaling pathways and cancer biology.

Estrogen receptor-IN-1 is a potent inhibitor of the estrogen receptor (ER), demonstrating IC50 values of 13 µM for ERα and 5 µM for ERβ. This compound is utilized in research to investigate estrogen signaling pathways and the role of estrogen receptors in various biological processes, including cancer progression and hormone-related disorders. Its selective inhibition provides a valuable tool for studying ER function and therapeutic potential in related diseases.

Fulvestrant-3-boronic acid is a potent estrogen receptor alpha (ERα) inhibitor that exhibits competitive binding with an IC50 of 4.1 nM. This compound effectively induces degradation of ERα in breast cancer cells, making it a valuable tool for research in estrogen receptor-related signaling pathways and breast cancer therapies. Its mechanism of action supports studies aimed at understanding ERα's role in tumor progression and treatment resistance.

Elacestrant (S enantiomer) is a selective estrogen receptor (ERR) inhibitor known for its oral bioavailability. This compound exhibits differential inhibition with IC50 values of 48 nM for ERα and 870 nM for ERβ, demonstrating its potential as a targeted therapeutic agent in estrogen-related disorders. Its application in research includes studies focused on elucidating estrogen signaling pathways and developing treatments for hormone-responsive cancers.

Elacestrant S enantiomer dihydrochloride is a selective estrogen receptor (ERR) inhibitor that targets the estrogen receptor with distinct pharmacological properties. This compound demonstrates reduced biological activity compared to its R enantiomer, offering potential applications in the study of estrogen signaling pathways. It serves as a valuable tool for researchers investigating the role of estrogen receptors in various biological processes and the development of therapies for estrogen receptor-positive cancers.

Raloxifene 6-Monomethyl Ether is a derivative of Raloxifene that selectively inhibits Estrogen Receptor α. This compound demonstrates significant biological activity, with an IC50 of 250 nM against MCF-7 breast cancer cells, leading to a pIC50 of 6.6. It is a valuable tool for research in hormone-dependent cancer studies and may provide insights into therapeutic strategies targeting estrogen signaling pathways.

4,4'-Oxydiphenol is a known estrogen receptor inhibitor, exhibiting an IC50 value of 60 μM. This compound manifests significant biological activity by modulating estrogen signaling pathways, making it a useful tool for exploring estrogen receptor-related mechanisms. It is pertinent for research applications in cancer biology, particularly in studies focused on hormone-dependent tumors and endocrine regulation.

RORγt inverse agonist 36 is a selective inverse agonist targeting the retinoid-related orphan receptor gamma t (RORγt). This compound modulates RORγt activity, leading to inhibition of Th17 cell differentiation and cytokine production. It is primarily utilized in research focused on inflammation and immunology, offering valuable insights into therapeutic approaches for autoimmune diseases.

CID 7309015 is a selective inhibitor of retinoic acid-related orphan receptor gamma (ROR-γ). This compound demonstrates significant potential in modulating inflammatory pathways, particularly in the context of NF-κB signaling and inflammatory arthritis research. CID 7309015 serves as a valuable tool for investigating the roles of ROR-γ in immune response and inflammatory diseases.

RORγt inhibitor 3 is a potent and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), which plays a crucial role in Th17 cell differentiation. This compound demonstrates high binding affinity and effectively modulates immune responses, making it particularly relevant for research in autoimmune disorders. Its efficacy has been validated in mouse models of experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA), highlighting its potential for therapeutic applications in inflammatory diseases.